论文部分内容阅读
目的探讨肿瘤坏死因子相关凋亡诱导配体(tumornecrosisfactorrelatedapoptosis-inducingligand,TRAIL)与其受体(TRAILR)在肝细胞肝癌中的表达及TRAIL联合应用化疗药对肝癌细胞的杀伤作用。方法采用免疫组化和原位杂交检测100例肝癌及癌旁组织中TRAIL及TRAILR的表达。用MTT法检测TRAIL与化疗药联合应用对肝癌细胞的杀伤作用。结果TRAIL在正常肝组织中无表达,在癌旁组织中的表达明显高于癌组织;肝癌组织中死亡受体(DR5、DR4)的表达量显著强于正常肝组织,诱捕受体为低表达,与正常肝组织相比,两者差异显著(χ2=4·68,P<0·05)。Ⅲ/Ⅳ期肿瘤死亡受体的表达显著低于Ⅰ/Ⅱ期(χ2=6·17,P<0·05)。联合使用亚细胞毒性剂量的化疗药大幅度提高了TRAIL的细胞毒活性。结论TRAIL与化疗药物联合运用具有协同杀伤肝癌细胞的作用。
Objective To investigate the expression of tumor necrosis factor associated-inducing ligand (TRAIL) and its receptor (TRAILR) in hepatocellular carcinoma (HCC) and the cytotoxic effect of TRAIL combined with chemotherapeutic agents on hepatoma cells. Methods Immunohistochemistry and in situ hybridization were used to detect the expression of TRAIL and TRAILR in 100 cases of hepatocellular carcinoma and its adjacent tissues. The killing effect of TRAIL combined with chemotherapeutic agents on hepatoma cells was detected by MTT assay. Results The expression of TRAIL was not detected in normal liver tissues, but significantly higher in adjacent tissues. The expressions of DR5 and DR4 in liver cancer tissues were significantly higher than those in normal liver tissues, and the expression of TRAIL receptor was low , Compared with normal liver tissue, the difference was significant (χ2 = 4.68, P <0.05). The expression of tumor death receptor in stage Ⅲ / Ⅳ was significantly lower than that in stage Ⅰ / Ⅱ (χ2 = 6.17, P <0.05). Chemotherapy with a combination of cytotoxic doses dramatically increased the cytotoxic activity of TRAIL. Conclusion The combined use of TRAIL and chemotherapeutic drugs has the effect of synergistically killing hepatoma cells.